http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CZ-261199-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d452ebbe234b18c80d0462dc24578da3 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B50-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-02 |
| filingDate | 1998-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a81ed4e0af0a93b6c781aaa58353b5b3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63bdaf5f1cfbaa0ada05bb44e793b8d0 |
| publicationDate | 2000-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CZ-261199-A3 |
| titleOfInvention | A method for increasing the accumulation of radiolabelled compounds in tissues |
| abstract | Administration of a radiolabeled compound in an over lasting period of timen»2 hours, better than 12 hours, greatly increases the maximumnof radioactivity that accumulates in the target cells. Efficiencynadministration of the radiolabelled compound may be about five timesnhigher than the bolus injection tone or short-term injection.nThis method increases the ratio of radioactivity between the tumor and the backgroundnby increasing the actual amount of radioligand accumulated inntumor cells. This method can be used in any wayna radiolabeled compound whose uptake in the cellsnis limited by binding to cellular receptors or transportnproteins. Where radiolabelled compounds are bound andnIn general, the ability of an unlabelled compound to compete with isnradioligandemically reduced. The primary factor influencingnretention time after intemalization is the physical half-life of the radioisotope,nnot its biological half-life. |
| priorityDate | 1998-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 747.